Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Krystexxa Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy 5.01.665

    Krystexxa (pegloticase) for refractory chronic gout

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.665 alerts

    Get alerted when Policy 5.01.665 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria, prior authorization guidance, and coverage stance for Krystexxa (pegloticase) in adults with refractory chronic gout for Bluecross Idaho members.

    Policy Summary
    PayerBluecross Idaho
    PolicyKrystexxa (pegloticase) for refractory chronic gout
    Policy CodePolicy 5.01.665
    Change TypeRevised — material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateDec 18, 2025
    Key ActionSubmit prior authorization with documentation of age (>18), refractory chronic gout, baseline serum uric acid >8 mg/dL, prior trials of allopurinol and febuxostat, and required clinical measures for continuation.
    SourceLink
    POLICY UPDATE CHANGES

    Updated policy statements with initial and continuing approval durations.

    Adopted Blue Cross of Idaho policy as revised, effective 04/01/2026.

    ≥18minimum age for initiation
    >8 mg/dLbaseline UA for initiation
    24 wksinitial auth duration
    1 yr

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    continuation auth duration
    8 mg q2wdosing schedule

    Coverage Criteria for Krystexxa (pegloticase)

    Initial Therapy

    Covered when ALL of the following are met:

    Initial treatment criteria: 1) Individual is > 18 years of age; AND 2) Diagnosed with refractory chronic gout; AND 3) Individual has ALL three: a) ≥3 gout flares in the past 18 months while on anti-gout therapy (excluding flares within the first month of starting xanthine oxidase inhibitor therapy), b) presence of one or more tophi, c) history of chronic gouty arthropathy (clinical or radiographic); AND 4) Reversible causes of gout have been considered and treated as indicated (eg, alcohol use, high-purine diet, obesity, offending medications); AND 5) Baseline serum uric acid > 8 mg/dL prior to initiation; AND 6) Failed, intolerant of, or contraindicated to: a) appropriately dosed allopurinol for ≥3 months with failure to achieve UA < 6 mg/dL (often requiring >300 mg/day up to 800 mg/day), b) appropriately dosed febuxostat for ≥3 months with failure to achieve UA < 6 mg/dL (titrated up to 80 mg/day), c) combination therapy of a xanthine oxidase inhibitor (allopurinol or febuxostat) plus probenecid for ≥3 months with failure to achieve UA < 6 mg/dL; AND 7) Continues to have frequent gout flares (>2 flares/year) or non-resolving subcutaneous tophi while using the above therapies.see node text

    Initial approval duration 24 weeks

    Continuation Therapy

    Covered when ALL of the following are met:

    Continuation criteria: I) Dosing is limited to 8 mg IV infusion every 2 weeks; AND II) There is clinically significant improvement in signs and symptoms (eg, reduced gout flares, tophus resolution, reduced joint pain); AND III) The two most recent serum uric acid levels are < 6 mg/dL (UA levels should be monitored prior to infusion).dosing and UA <6 mg/dL

    Continuation approval duration 1 year

    Not Medically Necessary

    Not medically necessary conditions: I) Asymptomatic hyperuricemia (uric acid >6.8 mg/dL without prior gout flares or subcutaneous tophi); OR II) Known G6PD deficiency; OR III) Concomitant use with oral urate-lowering therapy (eg, allopurinol, febuxostat, probenecid); OR IV) The above criteria are not met or use for all other indications.

    Not covered in listed conditions

    Krystexxa (pegloticase) should not be used in individuals with a known G6PD deficiency because of risk and because such use is explicitly listed as not medically necessary. Additionally, the policy states that concomitant administration of Krystexxa with oral urate‑lowering therapy (for example, allopurinol, febuxostat, probenecid) is considered not medically necessary and therefore is not covered.

    The policy identifies the following situations as not medically necessary for Krystexxa (pegloticase): asymptomatic hyperuricemia defined as uric acid >6.8 mg/dL without prior gout flares or subcutaneous tophi; known G6PD deficiency; and use in combination with oral urate‑lowering therapy (including but not limited to allopurinol, febuxostat, probenecid). Uses that do not meet the listed medical necessity criteria are also not covered.

    Coding and Laboratory Thresholds

    HCPCSHCPCS
    J2507Injection, pegloticase, 1 mg
    Serum uric acid thresholds
    Initiation thresholdBaseline serum uric acid > 8 mg/dL prior to initiation of Krystexxa (pegloticase)
    Continuation thresholdTwo most recent serum uric acid levels < 6 mg/dL prior to continuation infusions
    Monitoring frequency noteUric acid (UA) levels should be monitored prior to each infusion to document continuation criteria

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required (HCPCS J2507)

    Prior authorization is required for Krystexxa (pegloticase) billed with HCPCS code J2507. Initial requests must meet the policy's medical necessity criteria, including age, refractory chronic gout diagnosis, baseline serum uric acid > 8 mg/dL, and required prior medication trials.

    • Use HCPCS code J2507 (Injection, pegloticase, 1 mg) when submitting prior authorization requests.
    Step Therapy

    Required step therapy trials (allopurinol, febuxostat, combination)

    Before Krystexxa is authorized, document that the member failed, was intolerant of, or has contraindications to appropriately dosed allopurinol and febuxostat and to combination therapy with a xanthine oxidase inhibitor plus probenecid; each therapy must have been tried at appropriate dosing for at least 3 months without achieving serum uric acid <6 mg/dL.

    • Allopurinol: appropriately dosed ≥3 months (often >300 mg/day up to 800 mg/day) with UA not <6 mg/dL.

    Background

    Pegloticase (Krystexxa) is an intravenous uricolytic agent indicated for adults with refractory chronic gout. The policy clarifies circumstances under which Krystexxa is not medically necessary, including patients with asymptomatic hyperuricemia (uric acid >6.8 mg/dL without flares or tophi), individuals with known G6PD deficiency, and when used concomitantly with oral urate‑lowering therapies such as allopurinol, febuxostat, or probenecid. Providers should use these exclusions when assessing appropriateness of therapy and prior authorization requests.

    Definitions

    Refractory chronic gout — definition
    Core definitionRefractory chronic gout: gout persisting despite conventional therapy characterized by ≥3 gout flares in the past 18 months while on anti-gout therapy, presence of one or more tophi, and chronic gouty arthropathy (clinical or radiographic)
    Flare requirementThree (3) or more gout flares in the past 18 months while on anti-gout therapy (exclude flares within first month of starting xanthine oxidase inhibitor)
    Tophi requirementPresence of one or more tophi documented clinically
    Arthropathy requirementHistory of chronic gouty arthropathy defined clinically or radiographically as joint damage due to gout
    Reversible causesReversible causes of gout (eg, alcohol use, high purine intake, obesity, offending medications) must be considered and treated as indicated
    Policy Summary
    PayerBluecross Idaho
    PolicyKrystexxa (pegloticase) for refractory chronic gout
    Policy CodePolicy 5.01.665
    Change TypeRevised — material changes
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateDec 18, 2025
    Key ActionSubmit prior authorization with documentation of age (>18), refractory chronic gout, baseline serum uric acid >8 mg/dL, prior trials of allopurinol and febuxostat, and required clinical measures for continuation.
    SourceLink
    On This Page
    Coverage Criteria for Krystexxa (pegloticase)Coding and Laboratory ThresholdsPrior Authorization, Documentation, and Step TherapyBackgroundDefinitions
  1. Febuxostat: appropriately dosed ≥3 months with dose titration up to 80 mg/day and UA not <6 mg/dL.
  2. Combination of a xanthine oxidase inhibitor (allopurinol or febuxostat) plus probenecid: appropriately dosed ≥3 months with UA not <6 mg/dL.
  3. Documentation Required

    Required clinical documentation

    Include objective clinical documentation with the prior authorization: patient age (>18), diagnosis of refractory chronic gout, frequency of gout flares in the past 18 months, presence of tophi, evidence of chronic gouty arthropathy, baseline serum uric acid, and documentation of prior therapy trials and outcomes.

    • Age > 18 years and diagnosis of refractory chronic gout (≥3 flares in past 18 months, presence of tophi, chronic gouty arthropathy).
    • Baseline serum uric acid > 8 mg/dL prior to initiation.
    • Records showing trials, intolerances, contraindications, or failures of allopurinol, febuxostat, and combination therapy.
    • For continuation: two most recent serum uric acid levels < 6 mg/dL and evidence of clinical improvement (eg, reduced flares or tophus resolution).
    Denial Risk

    Denial risks: not medically necessary conditions

    Requests may be denied if the individual has conditions or uses that the policy lists as not medically necessary, including asymptomatic hyperuricemia, known G6PD deficiency, or concomitant use with oral urate-lowering therapy.

    • Asymptomatic hyperuricemia: uric acid > 6.8 mg/dL without prior gout flares or subcutaneous tophi.
    • Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
    • Concomitant use of Krystexxa with oral urate-lowering therapies (eg, allopurinol, febuxostat, probenecid).
    • Any request that does not meet the listed medical necessity criteria.